硕世生物：聘任涂小宝为公司副总经理

Group 1 - The core point of the article is the appointment of Mr. Tu Xiaobao as the Vice President of Shuoshi Biotechnology, which was decided by the board of directors after a nomination process [1] - For the fiscal year 2024, Shuoshi Biotechnology's revenue composition is 94.78% from the in vitro diagnostic industry and 5.22% from other businesses [1] Group 2 - As of the report, Shuoshi Biotechnology has a market capitalization of 6.5 billion yuan [2] - The Chinese innovative drug sector has generated 80 billion dollars in overseas licensing deals this year, indicating a hot secondary market in biomedicine [2]